An AbbVie clinical vet heading early oncology jumps ship to build his own team at NK cell-focused biotech
Making the leap from a mid-sized biotech into the ranks of pharma can be a chafing experience for executives used to a more flexible work environment — and that jump gets even harder during an acquisition. For Thorsten Graef, a clinical veteran who transitioned from Pharmacyclics into AbbVie, the move was a learning experience in terms of what sort of team he wanted to run.
Now, he’s getting his chance.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.